Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain in red
Wed, 31 Jul 11:30 am

Indian share markets have remained in red in the last two hours of trade. Barring IT, all other sectors are facing selling pressures.

The BSE-Sensex is down by 118 points and NSE-Nifty is down by 53 points. BSE Mid Cap and BSE Small Cap indices are down by 2% and 1.7% respectively. The rupee is trading at 61.02 to the US dollar.

IT shares are trading on a mixed note with Moser-Baer India and Tata Consultancy Services (TCS) leading the gains while CMC Ltd and HCL Infosystems are leading the losses. HCL Technologies, the country's fourth largest software exporter has announced its fourth quarter and full year results for FY13 (the Company follows a June year end). The quarterly net profit has risen by 41.6% on a YoY basis and 16.3% on a QoQ basis, backed by strong order wins. Revenues of the Noida-based company stand at Rs 69,440 m for 4QFY13, showing an 8 per cent growth sequentially, as compared to Rs 64,250 m reported in the previous quarter. For FY13, revenues are Rs 257,340 m, up by 22.4% YoY and the net profit is Rs 40,990m, up by 62.3% YoY. HCL Tech's share is trading up by 0.6%.

Indian Pharma shares are trading on a mixed note with Dr. Reddy's and Natco Pharma leading the gains while Strides Arcolab and Dishman Pharma are leading the losses. According to a leading financial news daily, The Delhi High Court (HC), in two separate cases, has asked the Government not to take coercive measures against Sun Pharma and Cipla till the next hearing. The HC has also ordered the two companies to furnish price lists of essential drugs they manufacture as mandated under the new Drug Price Control Order (DPCO) to domestic drug distributors and state drug controllers.

Sun Pharma and Cipla had challenged the Government on the specific provision under the drug price control order 2013, which mandated the pharma companies to ensure that their essential drugs should contain new price labels within a period of 45 days from the date of DPCO.

Since the court has not spelt out explicitly that drug retailers would have to sell at new prices notified under DPCO 2013, Cipla and Sun Pharma can interpret it as a temporary relief till the matter is finally decided or the court takes a different view. However, by asking the companies to send price lists to distributors and the drug regulator, the court has sent a clear message that the process of implementation of new DPCO is on. Cipla's share is trading down by 2% and Sun Pharma's share is trading down by 0.7%

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain in red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.